Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 6/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 7/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | RET | P07949 | 3/20 | 0.37 |
| ▸ | KIF5B | P33176 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2398434 | 0.74 | PDPK1 (0.45) | PDPK1PRKD3 | |
| SCHEMBL248137 | 0.73 | EGFR (0.45) | EGFRERBB2 | |
| SCHEMBL247658 | 0.72 | PRKDC (0.61) | — | |
| SCHEMBL1599442 | 0.72 | PDPK1 (0.78) | PDPK1DAPK3PRKD3FLT1RPS6KA3 | |
| SCHEMBL15006773 | 0.72 | RET (0.51) | PDPK1KDRKDM1ARETKIF5B | |
| SCHEMBL3410352 | 0.72 | EGFR (0.44) | PDPK1PDE3APDE10ADAPK3PRKD3 | |
| SCHEMBL2238301 | 0.71 | CHUK (0.38) | PRKD3 | |
| SCHEMBL250550 | 0.70 | PRKDC (0.50) | PDPK1PDE10ADAPK3PRKD3FLT1 | |
| SCHEMBL15006742 | 0.68 | PDPK1 (0.47) | PDPK1PDE10ADAPK3PRKD3FLT1 | |
| SCHEMBL27816759 | 0.67 | EGFR (0.56) | EGFRERBB2KDRRETKIF5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588457-B1 | PYRAZOLOQUINOLINE DERIVATIVES AS DNA-PK INHIBITORS | MERCK PATENT GMBH (DE) | 2014-11-05 | — | — | EP | disclosed |
| US-8802712-B2 | Pyrazoloquinolines | MERCK PATENT GMBH (DE) | 2014-08-12 | — | — | US | disclosed |
| US-20130150359-A1 | PYRAZOLOQUINOLINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-06-13 | — | — | US | disclosed |
| EP-2588457-A1 | PYRAZOLO-QUINOLINES | Merck Patent GmbH (DE) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012000632-A1 | PYRAZOLO-QUINOLINES | MERCK PATENT GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150359-A1 | PYRAZOLOQUINOLINES | PLK1, PKN3, PKN1 | PDPK1 67/4885PDE3A 1617/4885PDE10A 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.